Bleomycin is a type of medicine used to treat certain types of cancer. It works by stopping cancer cells from growing.
Every report comes from a Lived member, sent anonymously.
Have you tried Bleomycin for Hodgkin Lymphoma?
Bleomycin is a chemotherapy medicine given by injection to treat several cancers. In the US it is approved for Hodgkin lymphoma and non-Hodgkin lymphoma, testicular cancer, and squamous cell cancers (cancers of the thin, flat cells lining surfaces) of the head and neck, cervix, vulva and penis. It was once sold under the brand name Blenoxane, which is no longer marketed; today it is supplied as generic bleomycin. Bleomycin is almost always one part of a combination. It is the "B" in ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), a standard regimen for Hodgkin lymphoma, and in BEP (bleomycin, etoposide and cisplatin), a standard regimen for testicular cancer. It is also used in a different way to treat a malignant pleural effusion, a buildup of fluid around the lungs caused by cancer: placed into the chest cavity, it irritates the lining so the layers seal together and the fluid is less likely to return. Doctors sometimes use it for other cancers, such as Kaposi sarcoma related to HIV.
Bleomycin comes from a bacterium and is technically an antibiotic, but it is used only against cancer. Inside cells it breaks strands of DNA, the genetic material a cell must copy before it divides. Cancer cells that divide quickly are especially vulnerable, so the damage stops them from growing and multiplying. The body breaks bleomycin down with an enzyme found in most tissues, but the lungs and skin have very little of it. That is why those two organs bear most of its side effects. The kidneys clear most of the drug from the body, so kidney function affects how much is safe to give.
Bleomycin is given by a doctor or nurse in a hospital or clinic, never at home. For cancer treatment it is injected into a vein, a muscle or under the skin, usually once or twice a week as part of repeating chemotherapy cycles. The dose is based on body size, the cancer being treated, the other drugs in the regimen and kidney function, with lower doses for people whose kidneys clear it more slowly. People with lymphoma often receive a small test dose for the first one or two treatments and are watched afterward, because a rare severe reaction tends to happen early. Care teams also track the total amount given over the whole course, because lung risk climbs as that total rises. For a malignant pleural effusion, bleomycin is given once, as a liquid placed into the chest cavity through a chest tube. If a scheduled dose is missed, contact the treatment team to rearrange it.
Skin and nail changes are the most common effects, reported in about half of people. They include redness, rash, darkened or streaked skin, tenderness, thickening, blisters, nail changes and hair loss, and usually appear after a few weeks of treatment as the total dose builds. Fever, chills, mouth sores and vomiting can also occur, and loss of appetite and weight loss sometimes last well after treatment ends. The most serious risk is lung damage. About 1 in 10 people develop lung inflammation (pneumonitis), and in roughly 1 in 100 it progresses to permanent scarring of the lungs (pulmonary fibrosis) that can be fatal. The risk is higher in people over 70, in those with existing lung disease or reduced kidney function, and when the cumulative total over the whole course exceeds 400 units, but it can occur in young people and at low doses. New or worsening shortness of breath, difficulty breathing, wheezing or a new cough during or after treatment should be reported to the care team right away, especially when fever or chills come with it. About 1 in 100 people with lymphoma have a severe reaction that resembles a serious allergic reaction, with low blood pressure, confusion, fever, chills and wheezing. It usually follows the first or second dose and can start right away or several hours later. Contact the care team right away about fever, chills or feeling unwell after a dose. If severe trouble breathing, fainting or confusion starts after leaving the clinic, call 911. Rare blood vessel problems, including heart attack, stroke and Raynaud phenomenon (fingers turning white or blue in the cold), have been reported, mostly with combination chemotherapy.
Bleomycin leaves the lungs sensitive to oxygen. During surgery, oxygen at levels normally considered safe can injure lungs that have been exposed to it, so anyone who has received bleomycin should tell the surgeon, anesthesia team and dentist before any operation. The team can then keep oxygen as low as safely possible and manage fluids carefully. Because other cancer drugs given alongside bleomycin can add to lung and kidney strain, lung problems may appear at lower total doses in combination regimens. Tell the care team about existing lung disease, kidney disease and every medicine and supplement you take. Anyone who has had a severe reaction to bleomycin should not receive it again. Bleomycin can harm a developing baby. People who could become pregnant should avoid pregnancy during treatment and discuss contraception with the care team, and breastfeeding is not recommended while receiving it. Its effects on fertility have not been well studied in people, which is worth raising before treatment starts.
Bleomycin is usually given across the weeks or months of a chemotherapy course, alongside the other drugs in the regimen. In Hodgkin lymphoma and testicular cancer, tumors often respond within a couple of weeks; squamous cell cancers can take around three weeks to show improvement. Monitoring focuses on the lungs. The care team asks about breathing at each visit and may order chest x-rays or breathing tests that measure how well the lungs transfer oxygen. If lung changes appear, bleomycin is stopped while the team works out whether it is the cause, and treatment may continue with the other drugs. In advanced Hodgkin lymphoma, for example, people whose scans look clear after two cycles of ABVD may drop bleomycin for the rest of treatment; in a large trial this caused fewer lung problems without a significant loss of benefit. Kidney and liver blood tests are also checked. Lung scarring, if it develops, can be permanent, which is why reporting breathing changes early matters.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Bleomycin, what you've noticed, or ask the community a question.